Head to Head Review: ALT5 Sigma (AIFC) vs. Its Rivals

ALT5 Sigma (NASDAQ:AIFC) is one of 347 public companies in the “Financial Services” industry, but how does it contrast to its peers? We will compare ALT5 Sigma to similar companies based on the strength of its dividends, analyst recommendations, institutional ownership, earnings, valuation, profitability and risk.

Volatility & Risk

ALT5 Sigma has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Comparatively, ALT5 Sigma’s peers have a beta of 2.25, indicating that their average stock price is 125% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for ALT5 Sigma and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1	0	0	0	1.00
ALT5 Sigma Competitors	1905	6794	11489	414	2.51

As a group, “Financial Services” companies have a potential upside of 4.12%. Given ALT5 Sigma’s peers stronger consensus rating and higher possible upside, analysts clearly believe ALT5 Sigma has less favorable growth aspects than its peers.

Valuation and Earnings

This table compares ALT5 Sigma and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ALT5 Sigma	$24.84 million	-$344.51 million	1.42
ALT5 Sigma Competitors	$6.21 billion	$1.05 billion	11.23

ALT5 Sigma’s peers have higher revenue and earnings than ALT5 Sigma. ALT5 Sigma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 42.6% of shares of all “Financial Services” companies are held by institutional investors. 0.2% of ALT5 Sigma shares are held by company insiders. Comparatively, 21.5% of shares of all “Financial Services” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares ALT5 Sigma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-4,021.65%	-51.87%	-48.30%
ALT5 Sigma Competitors	-405.23%	-22.84%	-6.32%

Summary

ALT5 Sigma peers beat ALT5 Sigma on 13 of the 13 factors compared.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.